



Five-Year Mortality In Medicare Patients Undergoing Interventions For CLTI And IC Is Worse Than We Thought

Jeffrey J Siracuse, MD, MBA, FACS
 Professor of Surgery and Radiology
 Chief of Vascular and Endovascular Surgery
 Associate Chair of Surgery – Quality and Patient Safety
 Boston University, Chobanian and Avedisian School of Medicine
 Boston Medical Center

Disclosures

- WL Gore – Education grant
- VQI Vision - U01FD006936

Peripheral Arterial Disease

- Most common symptoms
 - Intermittent claudication (IC)
 - Chronic limb-threatening ischemia (CLTI), characterized by rest pain or tissue loss
- Most prevalent in Medicare patients
- Historically associated with poor survival
- Not well characterized in the long-term

Claudication

- Non-invasive vs invasive interventions
- Interventions more common
- Balance upfront risk with long-term durability and survival
- Goal of 50% success at 2 years

Chronic Limb Threatening Ischemia

- Open vs. endo
- Balance upfront risk vs. durability
- BASIL – at 2 years benefit is towards open interventions for limb salvage

Long-term Survival

- Historically poorly reported
- Improved understanding of survival in PAD Medicare patients could:
 - Help guide interventions
 - Set expectations for physicians and patients

Methods

- VISION VQI Medicare-linked data
- January 2010-May 2021
- Primary outcome - survival
- Kaplan-Meier
- Multivariable analysis

Methods


- Interventions
 - Peripheral vascular interventions (PVI)
 - Infrainguinal bypass (IIB)
 - Suprainguinal bypass (SIB)
- 5-year survival analysis

PVI

- 31,457 PVI procedures
- 45% for IC and 55% for CLTI
- Average age 75
- 57% male sex
- PVI for IC compared with CLTI were
 - younger
 - currently smoking
 - fewer comorbidities
 - more stenting
 - more aorto-iliac interventions

PVI - 5 Year Mortality

- Claudicants - 37.2%
- CLTI – 71.1%



PVI – Mortality Multivariable Analysis


Covariate	HR	95% CI	P-Value
End stage renal disease	3.1	2.9-3.3	<.001
CLTI vs. IC	2.02	1.93-2.12	<.001
Congestive heart failure	1.65	1.58-1.73	<.001
Anemia	1.43	1.36-1.51	<.001
COPD	1.37	1.32-1.43	<.001
Prior major amputation	1.32	1.03-1.68	<.05
Diabetes	1.23	1.18-1.28	<.001
Pre-operative anticoagulation	1.19	1.13-1.25	<.001
White race	1.14	1.08-1.2	<.001
Male sex	1.13	1.09-1.18	<.001
Current smoker	1.08	1.02-1.13	<.01
Coronary artery disease	1.08	1.04-1.13	<.001
Prior inflow stent	1.08	1.01-1.16	<.05
Age, year	1.04	1.04-1.05	<.001
Pre-admission home living	.54	.51-.57	<.001
Pre-operative statin	.86	.83-.9	<.001
Obesity	.86	.82-.9	<.002
Pre-operative aspirin	.87	.83-.91	<.001
Pre-operative aspirin and P2Y12 antagonist	.91	.86-.96	<.001

IIB

- 7978 IIB
- 27% for IC and 73% for CLTI
- Average age 73
- 64% male sex
- IIB for IC, compared with CLTI
 - younger
 - currently smoking
 - fewer comorbidities
 - fewer tibial targets

IIB - 5 Year Mortality

- Claudicants - 37.8%
- CLTI – 60%



IIB – Mortality Multivariable Analysis


Covariate	HR	95% CI	P-Value
End staged renal disease	3.56	3.1-4.1	<.001
Prior major amputation	2.7	1.7-24	<.05
CLTI vs. IC	1.6	1.45-1.77	<.001
Congestive heart failure	1.56	1.43-1.7	<.001
COPD	1.42	1.31-1.54	<.001
Anemia	1.35	1.24-1.48	<.001
Diabetes	1.2	1.11-1.3	<.001
Pre-operative anticoagulation	1.16	1.05-1.28	<.01
Male sex	1.15	1.06-1.24	<.001
White race	1.13	1.02-1.25	<.05
Age	1.05	1.05-1.06	<.001
Home living	.6	.53-.69	<.001
Obesity	.85	.78-.93	<.001
Aspirin	.86	.79-.95	<.001

SIB

- 2149 SIB
- 50% for IC and 50% for CLTI
- Average age 72
- 52% male sex
- SIB for IC, compared with CLTI
 - younger
 - currently smoking
 - fewer comorbidities
 - fewer extra-anatomical bypasses

SIB - 5 Year Mortality

- Claudicants - 33.8%
- CLTI – 53.8%



SIB – Mortality Multivariable Analysis

Covariate	HR	95% CI	P-Value
End-stage renal disease	3.87	2.6-5.8	<.001
Prior major amputation	2.24	1.3-3.85	<.01
Anemia	1.68	1.34-2.1	<.001
CLTI vs. IC	1.64	1.39-1.94	<.001
Congestive heart failure	1.39	1.13-1.72	<.01
COPD	1.33	1.13-1.72	<.001
Diabetes	1.21	1.02-1.44	<.05
Age	1.06	1.04-1.07	<.001
Pre-operative home living	.45	.32-.63	<.001
Aspirin	.82	.68-.99	<.05
Primary Medicare	.5	.33-.77	<.01

Conclusions

- Long-term survival in Medicare patients undergoing interventions for PAD is poor
- Particularly for patients with CLTI of whom almost two-thirds were not alive at 5 years
- Patients with ESRD, anemia, COPD, CHF at higher risk across all procedures

Conclusions

- Survival for patients undergoing elective interventions for IC was also poor
- These data can help guide discussions and expectations with patients about the type of intervention for CLTI and the benefits of any intervention for IC